Trials / Completed
CompletedNCT01829841
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
* Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. * The purpose of this study is to compare the efficacy and safety profile between Famitinib and Sunitinib in patients with metastatic renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib | Famitinib 25 mg p.o. qd |
| DRUG | Sunitinib | Sunitinib 50 mg p.o. qd |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2013-04-01
- Completion
- 2016-05-01
- First posted
- 2013-04-11
- Last updated
- 2018-05-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01829841. Inclusion in this directory is not an endorsement.